Skip to content

Efficacy and safety of oliceridine in patients with obesity undergoing painless gastroscopy

Efficacy and safety of oliceridine in patients with obesity undergoing painless gastroscopy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500107505
Enrollment
Unknown
Registered
2025-08-13
Start date
2025-09-01
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Need to undergo painless gastroscopy

Interventions

Propofol + Normal Saline Group (Group C):During anesthesia induction, 2 ml of normal saline and 2 mg/kg of propofol were administered.
Propofol + Oliceridine group (Group S):During anesthesia induction, 2 mg of oliceridine and 2 mg/kg of propofol were administered.

Sponsors

Hebei Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Aged 18 to 64 years, BMI greater than 28 kg/m^2, ASA grade I- II.

Exclusion criteria

Exclusion criteria: Severe respiratory depression, bronchial asthma, dysfunction of important organs, history of long-term use of sedative and analgesic drugs, those allergic to benzodiazepines, opioids and their components, should undergo treatment under endoscopy.

Design outcomes

Primary

MeasureTime frame
The incidence of hypoxemia;The success rate of endoscopic placement without any response (when the patient experiences dry vomiting, coughing, or body movement reaction during or within 1 minute of endoscopic placement);

Secondary

MeasureTime frame
The number and total amount of propofol infusions;Recovery time;The satisfaction of endoscopists;

Countries

China

Contacts

Public ContactWu Yajing

Hebei Provincial People's Hospital

843001577@qq.com+86 180 3182 5359

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026